Your browser doesn't support javascript.
loading
Gemtuzumab ozogamicin plus midostaurin in combination with standard '7 + 3' induction therapy in newly diagnosed AML: Results from the SAL-MODULE phase I study.
Röllig, Christoph; Schliemann, Christoph; Ruhnke, Leo; Fransecky, Lars; Heydrich, Björn-Niklas; Hanoun, Maher; Noppeney, Richard; Schäfer-Eckart, Kerstin; Wendelin, Knut; Mikesch, Jan-Henrik; Middeke, Jan Moritz; Reimann, Manja; Fiebig, Frank; Zukunft, Sven; Wermke, Martin; Serve, Hubert; Platzbecker, Uwe; Müller-Tidow, Carsten; Baldus, Claudia D; Bornhäuser, Martin.
Afiliación
  • Röllig C; Department of Internal Medicine I, University Hospital Dresden, TU Dresden, Dresden, Germany.
  • Schliemann C; Department of Medicine A, University Hospital Münster, Münster, Germany.
  • Ruhnke L; Department of Internal Medicine I, University Hospital Dresden, TU Dresden, Dresden, Germany.
  • Fransecky L; Department of Hematology and Oncology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
  • Heydrich BN; Department of Hematology and Oncology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
  • Hanoun M; Department of Hematology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
  • Noppeney R; Department of Hematology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
  • Schäfer-Eckart K; Department of Internal Medicine V, Nuremberg Hospital North, Paracelsus Medical University, Nuremberg, Germany.
  • Wendelin K; Department of Internal Medicine V, Nuremberg Hospital North, Paracelsus Medical University, Nuremberg, Germany.
  • Mikesch JH; Department of Medicine A, University Hospital Münster, Münster, Germany.
  • Middeke JM; Department of Internal Medicine I, University Hospital Dresden, TU Dresden, Dresden, Germany.
  • Reimann M; Department of Internal Medicine I, University Hospital Dresden, TU Dresden, Dresden, Germany.
  • Fiebig F; Department of Internal Medicine I, University Hospital Dresden, TU Dresden, Dresden, Germany.
  • Zukunft S; Department of Internal Medicine I, University Hospital Dresden, TU Dresden, Dresden, Germany.
  • Wermke M; Department of Internal Medicine I, University Hospital Dresden, TU Dresden, Dresden, Germany.
  • Serve H; Department of Internal Medicine II, University Hospital Frankfurt, Frankfurt, Germany.
  • Platzbecker U; Department of Internal Medicine I, Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany.
  • Müller-Tidow C; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
  • Baldus CD; Department of Hematology and Oncology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
  • Bornhäuser M; Department of Internal Medicine I, University Hospital Dresden, TU Dresden, Dresden, Germany.
Br J Haematol ; 204(6): 2254-2258, 2024 Jun.
Article en En | MEDLINE | ID: mdl-38593353
ABSTRACT
We conducted a phase I trial in newly diagnosed acute myeloid leukaemia (AML) to investigate the combination of two novel targeted agents, gemtuzumab ozogamicin (GO) and midostaurin, with intensive chemotherapy in FLT3-mutated AML and CBF leukaemia. Three dose levels of midostaurin and one to three sequential doses of 3 mg/m2 GO in combination with '7 + 3' induction were evaluated. Based on safety findings in 12 patients, our results show that 3 mg/m2 GO on Days 1 + 4 and 100 mg midostaurin on Days 8-21 can be safely combined with IC in newly diagnosed AML.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Protocolos de Quimioterapia Combinada Antineoplásica / Estaurosporina / Gemtuzumab Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Haematol Año: 2024 Tipo del documento: Article País de afiliación: Alemania
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Protocolos de Quimioterapia Combinada Antineoplásica / Estaurosporina / Gemtuzumab Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Haematol Año: 2024 Tipo del documento: Article País de afiliación: Alemania